- Patented nutraceuticals with retail distribution and consumer branding expertise
- MOU with cannabinoid pharma for research on NeutriSci products for new therapeutics
- Targeting forefront of new and innovative cannabinoid-based medical products in Canada
In business for nearly a decade, NeutriSci International Inc. (TSX.V: NU) (OTCQB: NRXCF) (FRA: 1N9) has become an established leader in the Canadian nutraceutical markets and continues to develop new sales channels throughout the U.S., Europe and Asia. The company is not only expanding its existing national retail footprint in Canada; it just entered into a major R&D Memorandum of Understanding with Scientus Pharma Inc. to develop, produce and distribute medical cannabinoid products for existing retail distribution networks across Canada.
With a history of specializing in the original formulation and production of products full of health-giving additives and clinically proven medicinal benefit, NeutriSci is recognized for product safety, quality and efficacy. Its sugar free Neuenergy® is a clinically proven, great tasting chewable tablet that provides a quick boost of energy and sharpens focus. Each tablet contains the equivalent anti-oxidants of 25,000 fresh blueberries. These anti-oxidants have a high level of bioavailability, and research suggests that “pterostilbene” is even more powerful than resveratrol.
“Neuenergy represents a healthy alternative to traditional energy products,” Canadian and International tennis star Genie Bouchard stated in a news release. Recognized throughout Canada and in tennis circles around the world, Bouchard recently inked a sponsorship deal with NeutriSci and said she’s “excited to partner with one of Canada’s up and coming brands.”
NeutriSci also produces its BlūScience™ line of products targeting memory, heart, anti-aging, weight management and focus & energy, all of which combine pterostilbene (pTeroPure) with other proprietary and specific health enhancing ingredients. One BlūScience™ capsule provides the same amount of pterostilbene found in over 500 cartons of blueberries. BlūScience products are specifically designed to support optimal health.
NeutriSci also plans to begin selling nu.thc™ and nu.cbd™ in Canada soon. These healthy, sugar-free cannabinoid tablets represent a market first and offer a metered dose of THC/CBD, combined with the increased bioavailability and powerful antioxidant properties of 125mg of the company’s patented pterostilbene.
The next big development for NeutriSci will likely come from its recently signed R&D Memorandum of Understanding with Scientus Pharma, a vertically-integrated biopharmaceutical focused on developing and commercializing pharmaceutical-grade medicinal cannabinoid derivative products.
NeutriSci’s products and their components are a natural fit for Scientus Pharma, which aims to develop new cannabinoid-based medicines. NeutriSci’s products have clinically proven anti-oxidant properties, enhance bioavailability and provide other health benefits, and Scientus Pharma will conduct research on NeutriSci’s products and their components in combination with various cannabinoids to develop new therapeutics. NeutriSci will initially bankroll the research activities, and both companies will have rights for further product development, testing and potential clinical trials.
“NeutriSci brings a wealth of retail distribution and consumer branding expertise,” Scientus Chairman Har Grover stated in a news release. “They have had success innovating with Neuenergy® and the brand has good presence in several health and wellness settings. Pterostilbene and related compounds present interesting targets for further research and we are looking forward to this collaboration.”
NeutriSci President Glen Rehman stated, “This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada. Scientus Pharma, along with its existing partnerships, is sure to be a dominant player in the cannabis space in Canada. Through a collaborative effort, we will incorporate NeutriSci’s IP, technology and ingredients with Scientus’ expertise, proprietary technical know-how, and resources. By leveraging both parties existing partnerships, we will be positioned to offer the national retail consumer a safe, effective, dose controlled product that completes our ‘plant to blood stream’ strategy.”
The R&D Memorandum of Understanding with Scientus Pharma will combine NeutriSci’s patented healthy products, retail distribution and consumer branding expertise with a leading cannabinoid biopharmaceutical intent on creating new therapeutics. As NeutriSci President Glen Rehman stated, it will “…position us at the forefront of developing new and innovative cannabinoid based medical products in Canada.”
This partnership could make an indelible mark in Canadian cannabis.
For more information, visit the company’s website at www.NeutriSci.com
For JGR Capital’s Research Note on NeutriSci International, see http://cnw.fm/F4I5o
More from CannabisNewsWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com